Autologous Mesenchymal Stromal Cells for Multiple Sclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 11, 2015

Primary Completion Date

November 27, 2017

Study Completion Date

November 15, 2018

Conditions

Relapsing-Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis

Interventions

DRUG

XCEL-MC-ALPHA

Single infusion

DRUG

Placebo

Single infusion

Trial Locations (1)

Hospital Vall Hebron, Barcelona

All Listed Sponsors

collaborator

Vall d'Hebron Research Institute (VHIR)

UNKNOWN

lead

Banc de Sang i Teixits

OTHER

NCT02495766 - Autologous Mesenchymal Stromal Cells for Multiple Sclerosis | Biotech Hunter | Biotech Hunter